All Stories

AbbVie, ADCs and the future of cancer care

This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates.

Jun 20, 2025 - 15:00
 0
AbbVie, ADCs and the future of cancer care
This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates.
Read More

Tags:

Previous Article

Kiko Milano speeds up UK e-commerce with new London dark store

Next Article

Fierce Biotech Layoff Tracker 2025: Prothena lays off 63% of staff after ph. 3 t...

Related Posts

Bluebird bio investor reluctance pays off as Carlyle, SK improve buyout offer by 67%

Bluebird bio investor reluctance pays off as Carlyle, S...

May 14, 2025  0

With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B

With Opella proceeds burning a hole in its pocket, Sano...

Jun 2, 2025  0

Novo Nordisk signs on to support ADA’s obesity advocacy division

Novo Nordisk signs on to support ADA’s obesity advocacy...

Jun 4, 2025  0